Lee Financial Co Sells 170 Shares of Danaher Corporation $DHR

by · The Cerbat Gem

Lee Financial Co reduced its position in Danaher Corporation (NYSE:DHR – Free Report) by 10.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,385 shares of the conglomerate’s stock after selling 170 shares during the period. Lee Financial Co’s holdings in Danaher were worth $284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of DHR. GHP Investment Advisors Inc. boosted its holdings in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after buying an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in shares of Danaher during the 4th quarter worth $27,000. Sierra Ocean LLC boosted its stake in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher in the 1st quarter worth $31,000. Finally, Dunhill Financial LLC raised its holdings in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 67 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of Danaher stock opened at $210.84 on Monday. The stock has a market cap of $150.97 billion, a price-to-earnings ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock has a 50 day moving average price of $199.94 and a 200-day moving average price of $199.54. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. Danaher’s quarterly revenue was up 3.4% compared to the same quarter last year. Equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of analyst reports. Wells Fargo & Company reduced their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Jefferies Financial Group reduced their target price on shares of Danaher from $260.00 to $230.00 and set a “buy” rating for the company in a report on Tuesday, April 22nd. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a report on Wednesday, April 23rd. TD Cowen boosted their price objective on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Finally, Barclays reiterated an “overweight” rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $247.61.

Check Out Our Latest Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).